Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR6 | P46095 | 19/20 | 0.67 |
| ▸ | USP2 | O75604 | 1/20 | 0.47 |
| ▸ | CASP1 | P29466 | 1/20 | 0.47 |
| ▸ | CASP7 | P55210 | 1/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17007752 | 0.88 | SMN1; SMN2 (0.57) | GPR6USP2CASP1CASP7SMN1; SMN2 | |
| SCHEMBL15567101 | 0.84 | GPR6 (0.65) | GPR6USP2CASP1CASP7SMN1; SMN2 | |
| SCHEMBL15566738 | 0.82 | GPR6 (0.67) | GPR6USP2CASP1CASP7SMN1; SMN2 | |
| SCHEMBL15567165 | 0.82 | GPR6 (0.93) | GPR6 | |
| SCHEMBL15566341 | 0.82 | GPR6 (0.93) | GPR6 | |
| SCHEMBL15565819 | 0.81 | GPR6 (0.76) | GPR6USP2CASP1CASP7SMN1; SMN2 | |
| SCHEMBL15566307 | 0.81 | GPR6 (0.90) | GPR6USP2CASP1CASP7SMN1; SMN2 | |
| SCHEMBL15568112 | 0.80 | GPR6 (0.73) | GPR6USP2CASP1CASP7SMN1; SMN2 | |
| SCHEMBL15565856 | 0.80 | GPR6 (1.00) | GPR6 | |
| SCHEMBL15567901 | 0.80 | GPR6 (0.90) | GPR6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9770452-B2 | Quinoxaline derivatives as GPR6 modulators | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2017-09-26 | — | — | US | disclosed |
| US-20170035775-A1 | QUINOXALINE DERIVATIVES AS GPR6 MODULATORS | ENVOY THERAPEUTICS, INC. | 2017-02-09 | — | — | US | disclosed |
| EP-2882722-B1 | QUINOXALINE DERIVATIVES AS GPR6 MODULATORS | TAKEDA PHARMACEUTICAL (JP) | 2016-07-27 | — | — | EP | disclosed |
| EP-2882722-A1 | QUINOXALINE DERIVATIVES AS GPR6 MODULATORS | Envoy Therapeutics Inc. (US) | 2015-06-17 | — | — | EP | disclosed |
| WO-2014028479-A1 | QUINOXALINE DERIVATIVES AS GPR6 MODULATORS | ENVOY THERAPEUTICS, INC. (US) | 2014-02-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170035775-A1 | QUINOXALINE DERIVATIVES AS GPR6 MODULATORS | GPR6, GRM6, GPR65 | GPR6 1/4885USP2 3163/4885CASP1 4168/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.